Esposito Antonio, Palmisano Anna, Toselli Marco, Vignale Davide, Cereda Alberto, Rancoita Paola Maria Vittoria, Leone Riccardo, Nicoletti Valeria, Gnasso Chiara, Monello Alberto, Biagi Andrea, Turchio Piergiorgio, Landoni Giovanni, Gallone Guglielmo, Monti Giacomo, Casella Gianni, Iannopollo Gianmarco, Nannini Tommaso, Patelli Gianluigi, Di Mare Luisa, Loffi Marco, Sergio Pietro, Ippolito Davide, Sironi Sandro, Pontone Gianluca, Andreini Daniele, Mancini Elisabetta Maria, Di Serio Clelia, De Cobelli Francesco, Ciceri Fabio, Zangrillo Alberto, Colombo Antonio, Tacchetti Carlo, Giannini Francesco
Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina 58, Milan, Italy.
Eur Radiol. 2021 Jun;31(6):4031-4041. doi: 10.1007/s00330-020-07622-x. Epub 2020 Dec 23.
Enlarged main pulmonary artery diameter (MPAD) resulted to be associated with pulmonary hypertension and mortality in a non-COVID-19 setting. The aim was to investigate and validate the association between MPAD enlargement and overall survival in COVID-19 patients.
This is a cohort study on 1469 consecutive COVID-19 patients submitted to chest CT within 72 h from admission in seven tertiary level hospitals in Northern Italy, between March 1 and April 20, 2020. Derivation cohort (n = 761) included patients from the first three participating hospitals; validation cohort (n = 633) included patients from the remaining hospitals. CT images were centrally analyzed in a core-lab blinded to clinical data. The prognostic value of MPAD on overall survival was evaluated at adjusted and multivariable Cox's regression analysis on the derivation cohort. The final multivariable model was tested on the validation cohort.
In the derivation cohort, the median age was 69 (IQR, 58-77) years and 537 (70.6%) were males. In the validation cohort, the median age was 69 (IQR, 59-77) years with 421 (66.5%) males. Enlarged MPAD (≥ 31 mm) was a predictor of mortality at adjusted (hazard ratio, HR [95%CI]: 1.741 [1.253-2.418], p < 0.001) and multivariable regression analysis (HR [95%CI]: 1.592 [1.154-2.196], p = 0.005), together with male gender, old age, high creatinine, low well-aerated lung volume, and high pneumonia extension (c-index [95%CI] = 0.826 [0.796-0.851]). Model discrimination was confirmed on the validation cohort (c-index [95%CI] = 0.789 [0.758-0.823]), also using CT measurements from a second reader (c-index [95%CI] = 0.790 [0.753;0.825]).
Enlarged MPAD (≥ 31 mm) at admitting chest CT is an independent predictor of mortality in COVID-19.
• Enlargement of main pulmonary artery diameter at chest CT performed within 72 h from the admission was associated with a higher rate of in-hospital mortality in COVID-19 patients. • Enlargement of main pulmonary artery diameter (≥ 31 mm) was an independent predictor of death in COVID-19 patients at adjusted and multivariable regression analysis. • The combined evaluation of clinical findings, lung CT features, and main pulmonary artery diameter may be useful for risk stratification in COVID-19 patients.
在非新冠病毒肺炎(COVID-19)背景下,已发现主肺动脉直径(MPAD)增大与肺动脉高压及死亡率相关。本研究旨在调查并验证COVID-19患者中MPAD增大与总生存率之间的关联。
这是一项队列研究,研究对象为2020年3月1日至4月20日期间,在意大利北部7家三级医院入院72小时内接受胸部CT检查的1469例连续COVID-19患者。推导队列(n = 761)包括前三家参与研究医院的患者;验证队列(n = 633)包括其余医院的患者。CT图像由对临床数据不知情的核心实验室进行集中分析。在推导队列中,通过调整后的多变量Cox回归分析评估MPAD对总生存率的预后价值。最终的多变量模型在验证队列中进行检验。
在推导队列中,中位年龄为69岁(四分位间距,IQR,58 - 77岁),男性537例(70.6%)。在验证队列中,中位年龄为69岁(IQR,59 - 77岁),男性421例(66.5%)。MPAD增大(≥ 31 mm)在调整后的(风险比,HR [95%置信区间]:1.741 [1.253 - 2.418],p < 0.001)和多变量回归分析(HR [95%置信区间]:1.592 [1.154 - 2.196],p = 0.005)中是死亡率的预测指标,同时还有男性性别、高龄、高肌酐、低通气良好肺容积以及高肺炎累及范围(c指数[95%置信区间] = 0.826 [0.796 - 0.851])。在验证队列中也证实了模型的判别能力(c指数[95%置信区间] = 0.789 [0.758 - 0.823]),使用第二位阅片者的CT测量结果时也是如此(c指数[95%置信区间] = 0.790 [0.753;0.825])。
入院时胸部CT显示MPAD增大(≥ 31 mm)是COVID-19患者死亡率的独立预测指标。
• 入院72小时内进行的胸部CT显示主肺动脉直径增大与COVID-19患者较高的院内死亡率相关。• 在调整后的和多变量回归分析中,主肺动脉直径增大(≥ 31 mm)是COVID-19患者死亡的独立预测指标。• 综合评估临床发现、肺部CT特征和主肺动脉直径可能有助于COVID-19患者的风险分层。